Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Randomized, Double-Blind, Placebo-Controlled Phase II Study To Determine The Safety And Efficacy Of Oral Ifetroban In Patients With Idiopathic Pulmonary Fibrosis (IPF)
Jacksonville, FL
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
-
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study Of The Efficacy And Safety Of Inhaled Treprostinil In Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate the safety and effectiveness of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
-
An Open-label Extension Study Of Inhaled Treprostinil In Subjects With Idiopathic Pulmonary Fibrosis
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with fibrotic interstitial lung disease
Contact Us for the Latest Status
Closed for Enrollment
-
A Double-Blind, Randomized, Placebo Controlled Study Of The Efficacy And Safety Of Three Doses Of Orvepitant In Subjects With Chronic Refractory Cough
Jacksonville, FL
Rochester, MN
The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of chronic refractory cough.
-
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study To Assess The Efficacy And Safety Of Simtuzumab (GS-6624) In Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to determine if Simtuzumab (GS-6624) is safe and effective in treating Idiopathic Pulmonary Fibrosis.
-
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study To Assess The Efficacy And Safety Of Lebrikizumab In Patients With Idiopathic Pulmonary Fibrosis
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background idiopathic pulmonary fibrosis (IPF) therapy or as combination therapy with pirfenidone background therapy in participants with idiopathic pulmonary fibrosis. Participants will be randomized to receive either lebrikizumab or placebo subcutaneously (SC) every 4 weeks.
-
A Randomized, Double-blind, Active-controlled 52-week Study With An Open-label Extension To Evaluate The Efficacy And Safety Of Benralizumab Compared To Mepolizumab In The Treatment Of Eosinophilic Granulomatosis With Polyangiitis (EGPA) In Patients Receiving Standard Of Care Therapy
Jacksonville, FL
This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection every 4th week in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE period is intended to allow each patient at least 1 year of treatment with open-label benralizumab 30 mg administered SC every 4th week (earlier enrolled patients may therefore be in the OLE for longer than 1 year).
-
A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study To Evaluate The Efficacy And Safety Of Bexotegrast (PLN-74809) For The Treatment Of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate the effectiveness and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
-
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study Of The Efficacy And Safety Of Inhaled Treprostinil In Subjects With Idiopathic Pulmonary Fibrosis
Jacksonville, FL
Rochester, MN
The primary objective of this study is to evaluate the safety and effectiveness of inhaled treprostinil in subjects with Idiopathic Pulmonary Fibrosis (IPF).
-
A Treatment Protocol To Allow Patients In The US With Idiopathic Pulmonary Fibrosis Access To Pirfenidone
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
This is an open label multi-center program to allow patients in the US with IPF access to treatment with pirfenidone.
-
Biomarker Modulation and the Inhibition of Natural Killer Type 1 (NKT1) Cells by Oral GRI-0621 in Patients with Idiopathic Pulmonary Fibrosis (IPF)
Jacksonville, FL
The purpose of this study is to determine the safety and tolerability of oral GRI-0621 as assessed by clinical labs and adverse events (AEs) after 12 weeks of treatment.
-
Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
Jacksonville, FL
This is a mechanistic research study to evaluate the relationship between cough, reflux, and aspiration in patients with systemic sclerosis (scleroderma).
.